The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) provided specific advice on use of metformin, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in patients with diabetes and chronic kidney disease.
People who time-restricted their eating had decreased body weight and fat mass and improved lipid values but did not show improvements in waist circumference, HbA1c level, or blood pressure, a systematic review and meta-analysis found.
Researchers presented older adults with type 2 diabetes with three scenarios in which deintensification may be indicated—poor health, limited life expectancy, and high hypoglycemia risk—and found that 8%, 4%, and 75%, respectively, viewed deintensification positively.
A large trial compared insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) receptor agonist, and a dipeptidyl peptidase-4 inhibitor as second-line therapy, while a modeling study considered GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as first-line agents.
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status
The combination of efficacy and safety data from a recent placebo-controlled trial and other research shows sodium-glucose cotransporter-2 inhibitors to be an important treatment for heart failure with preserved ejection fraction (HFpEF) regardless of patients' diabetes status, according to an ACP Journal Club commentary.
An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
A potential issue with the Medtronic MiniMed 600 Series Insulin Pump System's communication protocol could allow unauthorized access to the device, the FDA said.